share_log

Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix Announces Warrant Repricing and One-Year Extension

Resverlogix 宣布认股权证重新定价并延长一年
newsfile ·  2023/06/30 06:00

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants") will be amended. Commencing on July 17, 2023, the exercise price of 24,508,489 Warrants (currently exercisable at prices ranging from $0.24 to $1.00 per share) will be reduced to $0.20 per share, and the expiry date of 10,713,505 of the Warrants that currently expire between April 26, 2024 and June 6, 2025 will be extended by one year. All other terms of all the Warrants will remain unchanged. 1,500,000 warrants held by insiders of the Company will not be amended; the warrants listed for trading that expired on June 7, 2023 were not eligible for amendment.

加拿大阿尔伯塔省卡尔加里-(Newsfile Corp.-2023年6月29日)-Resverlogix Corp.(多伦多证券交易所股票代码:RVX)(以下简称“Resverlogix”或“公司”)宣布,其27,461,157份普通股认购权证(以下简称“认股权证”)的某些部分将被修订。自2023年7月17日起,24,508,489份认股权证的行使价格(目前可行使的价格为0.24美元至每股1.00美元)将降至每股0.20美元,目前到期的10,713,505份权证的到期日为2024年4月26日和2025年6月6日将延长一年。所有认股权证的所有其他条款将保持不变。本公司内部人士持有的1,500,000份权证将不会修订;于2023年6月7日到期的上市交易权证不符合修订资格。

The Company has received approval of the extension and repricing from the TSX, subject to satisfaction of customary conditions. The net proceeds from the exercise of Warrants will be used for research and development activities, general and administrative expenses, working capital needs and general corporate purposes.

该公司已获得多伦多证券交易所对延期和重新定价的批准,但须满足惯常条件。行使认股权证所得款项净额将用于研发活动、一般及行政开支、营运资金需要及一般企业用途。

About Resverlogix

关于Resverlogix

Founded in 2001, Resverlogix is a Calgary-based, late-stage, biotechnology company and the world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix成立于2001年,是一家总部设在卡尔加里的晚期生物技术公司,是表观遗传学领域的世界领先者,目标是为慢性病患者开发一流的治疗方法。

Our new class of epigenetic therapies are designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.

我们的新型表观遗传疗法旨在调节致病基因的表达。我们的目标是通过将因心血管疾病等严重疾病而改变的生物功能恢复到更健康的状态来改善患者的生活。

The Company's clinical program is focused on evaluating our lead candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.

该公司的临床计划侧重于评估我们治疗心血管疾病和相关合并症以及新冠肺炎后遗症的主要候选药物阿帕贝酮。

Resverlogix has partnered with EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).

Resverlogix与全球生命科学行业下一代商业服务的先驱EVERSANA公司建立了合作伙伴关系,以支持用于心血管疾病、新冠肺炎后疾病和肺动脉高压的阿帕贝酮在加拿大和美国的快速商业化。Resverlogix普通股在多伦多证券交易所(多伦多证券交易所市场代码:RVX)交易。

Follow us on:

请跟随我们:

  • Twitter: @Resverlogix_RVX
  • LinkedIn:
  • 推特:@Resverlogix_rvx
  • LinkedIn:

For further information please contact:

欲了解更多信息,请联系:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252

投资者关系
电子邮件:ir@resverlogix.com
电话:403-254-9252

Forward-Looking Statements:

前瞻性陈述:

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the repricing and extension of the Company's warrants. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

本新闻稿可能包含某些根据适用的加拿大证券法定义的不基于历史事实的前瞻性信息,包括但不限于包含“相信”、“预期”、“计划”、“打算”、“将”、“应该”、“预期”、“继续”、“估计”、“预测”以及其他类似表述的陈述。特别是,本新闻稿包括与公司认股权证的重新定价和延长有关的前瞻性信息。我们的实际结果、事件或发展可能与这些前瞻性陈述中明示或暗示的结果、事件或发展大不相同。我们不能保证任何事件或预期都会发生或实现。就其性质而言,前瞻性陈述受许多假设和风险因素的影响,包括在我们的年度信息表格和最新的MD&A中讨论的那些,这些陈述通过引用并入本文,并可通过SEDAR获得,网址为:。本新闻稿中包含的前瞻性陈述明确地受到这一警示声明的限制,并且是在本新闻稿发布之日作出的。除法律要求外,公司没有任何意图,也没有义务或责任更新或修改任何前瞻性陈述,无论是由于新信息、未来事件或其他原因。

To view the source version of this press release, please visit

要查看本新闻稿的源版本,请访问

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发